-
Product Insights
Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) - Drugs In Development, 2023’, provides an overview of the Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Drugs In Development, 2023’, provides an overview of the Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Polycystic Kidney Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycystic Kidney Disease - Drugs In Development, 2023’, provides an overview of the Polycystic Kidney Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Retinal Degeneration – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinal Degeneration - Drugs In Development, 2023’, provides an overview of the Retinal Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinal Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drugs In Development, 2023’, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) - Drugs In Development, 2023’, provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Duchenne Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Duchenne Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Neuroblastoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroblastoma - Drugs In Development, 2023’, provides an overview of the Neuroblastoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Recessive X Chromosome Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Recessive X Chromosome Disorders - Drugs In Development, 2023’, provides an overview of the Recessive X Chromosome Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recessive X Chromosome Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VP-001 in Retinitis Pigmentosa (Retinitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VP-001 in Retinitis Pigmentosa (Retinitis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VP-001 in Retinitis Pigmentosa (Retinitis) Drug Details: VP-001 is under...